Completed PHASE2 INTERVENTIONAL 2-arm NCT02524262

L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde

Slow-release L-cysteine Capsule Prevents Carcinogenic Gastric Acetaldehyde Exposure in Helicobacter-associated Atrophic Gastritis

Sponsor: Biohit Oyj, Helsinki, Finland

Conditions Gastritis, Atrophic

Interventions Slow-release L-cysteine

Updated 7 times since 2017 Last updated: Jan 21, 2016 Started: Dec 31, 2012 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02524262, this PHASE2 trial focuses on Gastritis, Atrophic and remains completed. Sponsored by Biohit Oyj, Helsinki, Finland, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Apr 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Apr 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biohit Oyj, Helsinki, Finland
CTC Clinical Trial Consultants AB
Per Hellström
University of Helsinki
Åbo Akademi University

Data source: Uppsala University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uppsala, Sweden